Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice

Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice

In recent years, sarcopenic obesity has been considered central pathological factors in diabetes. This study aimed to compare the effect of luseogliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), on sarcopenic obesity in comparison to that of a low-carbohydrate diet (LCD). Twenty-week-...

Full description

Bibliographic Details
Main Authors: Shinnosuke Hata, Takuro Okamura, Ayaka Kobayashi, Ryo Bamba, Tomoki Miyoshi, Hanako Nakajima, Nobuko Kitagawa, Yoshitaka Hashimoto, Saori Majima, Takafumi Senmaru, Hiroshi Okada, Emi Ushigome, Naoko Nakanishi, Hiroshi Takakuwa, Ryoichi Sasano, Masahide Hamaguchi, Michiaki Fukui
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Nutrients
Subjects:
sodium-glucose co-transporter-2 inhibitor
luseogliflozin
sarcopenia
sarcopenic obesity
metabolites
gut microbiota
Online Access:https://www.mdpi.com/2072-6643/14/17/3531

Internet

https://www.mdpi.com/2072-6643/14/17/3531

Similar Items